Drug Type
Synthetic peptide
Synonyms
Elcatonin (JP17/INN), HC 58, HC-58
+ [7]
Target
CALCR
Action
inhibitors
Mechanism
CALCR inhibitors(Calcitonin receptor inhibitors)
Therapeutic Areas
Endocrinology and Metabolic Disease Skin and Musculoskeletal Diseases
Active Indication
Familial Paget's Disease of Bone Hypercalcemia Osteoporosis
Inactive Indication
Hemiplegia Stroke
Originator Organization
Asahi Kasei Corp.
Active Organization
Asahi Kasei Corp. Shandong Luye Pharmaceutical Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest Phase Approved
First Approval Date
Japan (15 Jun 1982),
Osteoporosis
Regulation Orphan Drug (United States)
Login to view timeline
Molecular Formula C148H244N42O47
InChIKey DDPFHDCZUJFNAT-PZPWKVFESA-N
CAS Registry 60731-46-6
Sequence Code 1000323
Source: *****
5 Clinical Trials associated with Elcatonin
ChiCTR2500106599 / Not yet recruiting Not Applicable IIT
A prospective, randomized controlled study of elcatonin treatment for acute bone loss in perioperative period of fracture surgery
Start Date 01 Aug 2025
Sponsor / Collaborator
Peking Union Medical College Hospital
ChiCTR2400083358 / Not yet recruiting Early Phase 1 IIT
Efficacy of Calcitonin in Patients with Lumbar Spinal Stenosis and Concomitant Osteoporosis: A Prospective Randomized Controlled Study Protocol
Start Date 22 Apr 2024
Jiangsu Province Hospital of Traditional Chinese Medicine
[ +1]
ChiCTR-IPR-14005501 / Recruiting Phase 4 IIT
Evaluate the effectiveness and safety of elcatonin in the treatment of osteoporosis with lumbar canal stenosis: a multicenter, double-minded, randomized, placebo cnotrolled clinical study
Start Date 08 Oct 2014
Institute Of Basic Research In Clinical Medicine,China Academy Of Chinese Medical Sciences
100 Clinical Results associated with Elcatonin
Login to view more data
100 Translational Medicine associated with Elcatonin
100 Patents (Medical) associated with Elcatonin
233 Literatures (Medical) associated with Elcatonin
01 Apr 2023·International journal of surgery case reports
A case report of effective intra-articular elcatonin administration in a patient with osteonecrosis of the lunate
Author: Ikeda, Jun ; Inagaki, Katsunori ; Nagai, Takashi ; Tomita, Kazunari ; Kawasaki, Keikichi ; Kubo, Kazutoshi
INTRODUCTION AND IMPORTANCE:
Although corticosteroids are effective for bronchial asthma, they are associated with various side effects, such as osteonecrosis of the femoral head and tibial condyle and osteoporosis. Here, we report a patient who was on corticosteroids for a long period of time due to severe asthma, which was thought to have led to lunate osteonecrosis of both wrist joints. Calcitonin (elcatonin), an osteoporosis drug, was administered to the wrist joint.
CASE PRESENTATION:
Allergy to anesthetics and various non-steroidal anti-inflammatory drugs (NSAIDs) made surgical treatment not possible and pain control difficult. In addition, pain in the wrist joint interfered with activities of daily living (ADLs). When calcitonin was administered intra-articularly into the wrist joint, the pain in the wrist joint was relieved and ADLs were improved. However, the pain-suppressing effect lasted only 1 week, and pain returned to the original state by the second week after treatment. Repeated injections were necessary every 2 weeks.
CLINICAL DISCUSSION:
This is the first report of the effectiveness of intra-articular calcitonin in a patient with osteonecrosis of the lunate. This treatment may be applicable to patients with allergies to anesthesia and NSAIDs.
CONCLUSION:
In the present case, calcitonin administered intra-articularly to the wrist appeared to be effective in pain control for steroid-induced lunate osteonecrosis.
Show all
01 Jan 2023·BioMed research international
Retracted: Impact of Alendronate Sodium plus Elcatonin on Postoperative Bone Pain in Patients with Osteoporotic Fractures
Author: BioMed Research International
[This retracts the article DOI: 10.1155/2022/1213278.].
01 Jul 2022·International journal of hematology
Diffuse 18F-fluorodeoxyglucose uptake in the bone marrow of an elderly man with B-cell lymphoma
Letter
Author: Nakatani, Koya ; Notohara, Kenji ; Sakata, Etsuro ; Ueda, Yasunori ; Saito, Kenki
An 89-yr-old man with a history of right lung adenocarcinoma, left lung squamous cell carcinoma, and penile squamous cell carcinoma presented with lower back pain persisting for 1 mo and general pain and weakness in both lower limbs persisting for 10 days.A bone marrow biopsy revealed a monotonous increase in small lymphocytes with pale cytoplasm and CD20 positivity.To mitigate acute kidney injury with hypercalcemia, treatment with hydration, elcatonin, and zoledronic acid was initiated.Subsequently, rituximab and a reduced dose of THP-COP therapy (cyclophosphamide, pirarubicin, vincristine, and prednisolone) were started.The patient's renal function improved rapidly with the above treatment.Reduction in bone pain also improved his ability to perform activities of daily living.The soluble IL-2 receptor level after the second course of rituximab and THP-COP therapy was 380 U/mL, indicating dramatic improvement in the patient's condition.
100 Deals associated with Elcatonin
Approved
10 top approved records.
Developing
10 top R&D records.
Indication
Phase
Evaluation
View All Results
Boost your research with our translational medicine data.
login or view full example data
Boost your decision using our deal data.
Boost your research with our Core Patent data.
Identify the latest clinical trials across global registries.
Accelerate your research with the latest regulatory approval information.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
May 2025 Patent Highlights Patsnap Synapse JMC Annotation Spotlight: Analysis of Breakthrough Therapeutics
